History
Acute inflammatory demyelinating polyneuropathy is known as the most common form of Guillain-Barré syndrome. Guillain-Barré syndrome itself began to be widely known in 1916, when French neurologists described as a single syndrome the combination of acutely progressive paralysis of the arms and legs, loss of tendon reflexes, and the characteristic finding of high protein in the cerebrospinal fluid without a large increase in cell count. At that time, because "suddenly ascending paralysis" can also appear with many causes (infection, toxicity, spinal cord disease, and others), distinguishing it clinically was highly meaningful.
Later, in the 1950s and 1960s, it became clearer pathologically that the most common form of this syndrome is an inflammatory disease in which the myelin of the peripheral nerves (the insulating layer that wraps the nerves and speeds the conduction of electrical signals) is damaged by an immune response. From this time, the expression "acute inflammatory demyelinating polyneuropathy" gradually became established, and the fact that electrophysiological changes suggesting demyelination (myelin damage) can be observed on nerve conduction studies greatly aided diagnosis.
In the 1990s, it became known that in addition to the form in which myelin damage predominates, there are axonal variants in which the nerve axon itself (the central line along which electrical signals travel) is more severely damaged. This strengthened the recognition that Guillain-Barré syndrome is not a single disease but a "spectrum" grouping several forms.
An important point in the history of treatment is that clinical trials confirmed that corticosteroids, contrary to expectations, do not have a clear effect. Immunotherapies such as plasma exchange and intravenous immunoglobulin (IVIg) became established as treatments that hasten recovery, and in recent studies, targeted therapies such as complement (immune protein) inhibition are being investigated as new options.
Causes
The direct cause of acute inflammatory demyelinating polyneuropathy is "a phenomenon in which one's own immune system attacks the peripheral nerves." Why this begins cannot be fully explained by a single factor, but the most common course is one in which "the immune response after an infection goes badly awry and attacks the nerves." In fact, in many patients, a respiratory infection such as a cold or a gastrointestinal infection typified by diarrhea often precedes the onset of symptoms by 1 to 6 weeks.
Notably, infection with Campylobacter jejuni, which causes enteritis, is known to be closely related to Guillain-Barré syndrome. Associations have also been reported with infections such as cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and influenza. The important point, however, is that most people who experience these infections do not progress to Guillain-Barré syndrome. It can be understood that, even among people with the same infection, only a very small number have an immune response that is "wrongly aimed at the nerves."
Rarely, cases occurring after surgery or after vaccination have also been reported. However, it is very difficult to establish causality, and infection itself is often a stronger risk factor for Guillain-Barré syndrome. Recent studies also present the view that even if there is a vaccine-related risk, it is very small, and that the infections that vaccines prevent may actually increase the risk of Guillain-Barré syndrome more.
In summary, the cause lies not so much in "a specific bacterium or virus directly destroying the nerves" as in the immune system malfunctioning after an infection or immune stimulation, mistaking components of the nerve myelin for an "enemy" and attacking them.
Genetic Epidemiology
Genetic epidemiology is a perspective that connects "who is more likely to get the disease" with genetic differences. Acute inflammatory demyelinating polyneuropathy is closer to an acquired immune disease than to a hereditary disease. In other words, it is difficult to regard it as a disease caused by a single specific gene, and it is more realistic to consider that multiple genetic predispositions act together with environmental factors (such as infection).
In response to the question "why, after an infection, does the immune system attack the nerves in some people?", recent studies suggest that genetic differences that regulate the strength and direction of the immune response may be partly involved. For example, genetic variants that regulate the inflammatory response, genetic factors related to complement activation, the reactivity of macrophages (inflammatory cells), and individual differences in the regulatory circuits that suppress autoimmunity are mentioned as predispositions.
In current clinical practice, there is no standardized method of using genetic testing to predict "whether Guillain-Barré syndrome will develop" or to determine in advance "whether it will be the demyelinating type." The message of genetic epidemiology is not that "heredity is everything" but only that "it can be a clue that explains vulnerability," and far more important than heredity is quickly recognizing neurological symptoms that appear after an infection and seeking medical care.
General Epidemiology
Guillain-Barré syndrome is a relatively rare disease, known to occur in roughly 1 to 2 people per 100,000 population each year. Acute inflammatory demyelinating polyneuropathy is mentioned as the most common form among these in North America, Europe, and other regions. The incidence tends to increase with age, and there are reports that it is slightly more common in men than in women.
Seasonal and regional differences have also been reported. These are likely ultimately linked to "which infections are circulating," and in certain regions axonal variants are reported more frequently. Recent studies point out that traditional classifications often do not fully match the actual pathology, so caution is needed with simple comparisons.
A clinically important epidemiological fact is that this disease is a "neurological emergency." Some patients may develop weakness of the respiratory muscles and need a ventilator, and dangerous complications can also arise from autonomic instability. Most people recover, but recovery can take weeks to months, and some still have sequelae after a year, making it a disease that places a heavy burden on individuals and families.
Pathogenesis
The pathogenesis explains "why the immune system attacks the nerves and how paralysis occurs." In acute inflammatory demyelinating polyneuropathy, the myelin that wraps the peripheral nerves and the Schwann cells that make it are understood to be the targets of the immune response. Because myelin acts as an insulator that helps electrical signals travel rapidly by "saltatory conduction," when the myelin is stripped away, nerve signals slow down or are interrupted and the muscles cannot move properly.
In many cases, the most widely accepted explanation is that antibodies or immune cells produced after an infection "mistake" structures similar to nerve components and attack them. This is called molecular mimicry. In particular, in some variants, antibodies against glycolipids (gangliosides) on the nerve surface are identified. However, in the demyelinating type, target antibodies are not always found as clearly as in the axonal type, and the explanation that the inflammatory process in which T cells and macrophages strip away myelin is central is emphasized.
Recent studies highlight the view that "demyelination" and "axonal damage" are not completely separate processes; rather, myelin is disrupted early on, and axonal damage later overlaps with it and can determine the prognosis.
Recent studies repeatedly mention that a cascade of immune proteins called complement can be activated on the nerve surface and increase the damage. For this reason, treatments that block the entry point of the complement pathway (e.g., inhibition of a specific complement protein) are being studied as new treatment targets.
Symptoms
The most typical onset of acute inflammatory demyelinating polyneuropathy is "a feeling that the legs are losing strength and that the weakness is moving upward." At first, it may begin with stairs becoming difficult, the feet dragging, or difficulty standing for long. It often progresses relatively symmetrically on both sides and can worsen rapidly over days to weeks.
Sensory symptoms are also common. They may appear as numbness, tingling, or a pins-and-needles sensation in the hands and feet, back or lower back pain, or muscle pain. Although "paralysis" is central, it is important that considerable pain and discomfort can accompany it. There may also be cases in which the facial muscles weaken so that facial expressions become awkward, swallowing becomes difficult, or speech becomes slurred.
Feeling short of breath, having difficulty taking a deep breath, or feeling that one's cough is weakening may be warning signs. These indicate that respiratory muscle weakness is progressing, and prompt monitoring and hospitalization may be needed. In addition, autonomic symptoms such as dizziness, palpitations, a feeling of abnormal sweating or absence of sweating, constipation, or urinary problems may appear.
A major feature of the symptoms is the combination of "rapidly progressing weakness" and "decreased or absent reflexes." After the symptoms progress, there is often a "plateau phase (a period in which it does not get worse)" for a certain time, followed by gradual recovery.
Signs
Signs are the objective findings confirmed by the examiner. The most important sign is decreased or absent tendon reflexes. For example, it is common for the knee or ankle reflex to weaken or disappear. On muscle strength testing, functions such as lifting the ankle, extending the knee, and lifting the hip may be weakened, making walking difficult.
On sensory testing, decreased sensation starting from the toes, decreased vibration sense, or changes in pain and temperature sensation may be observed. However, the severity of sensory abnormalities varies from person to person, and it is also common for motor symptoms to be more prominent. If the cranial nerves are involved, signs such as bilateral facial paralysis, abnormal eye movements, and swallowing difficulties may appear.
Signs of respiratory muscle weakness are especially important. If findings such as shortness of breath when speaking, a feeling of greater breathlessness when lying down, a weakened cough, or reduced vital capacity appear, intensive care may become necessary. Autonomic signs may include large swings in blood pressure, irregular heartbeat, or abnormal sweating.
The core of the signs is "symmetric muscle weakness + decreased or absent reflexes," which may be accompanied by sensory abnormalities, pain, cranial nerve symptoms, and respiratory or autonomic problems.
Screening
For this disease, rather than screening in the form of "mass checkups," noticing symptoms early and having them quickly suspected at a medical facility is effectively the closest thing to screening. In other words, if within 1 to 6 weeks after a cold or enteritis the legs lose strength, numbness progresses rapidly, or walking becomes difficult within a few days, it is most important to keep in mind the possibility of an "acute peripheral nerve disease."
For screening at the clinic level, the neurological examination is key. The strength, tendon reflexes, sensation, and gait of both arms and legs are quickly checked. If reflexes are markedly decreased and the weakness is progressing upward, the Guillain-Barré syndrome spectrum is strongly suspected.
Screening for respiratory risk is also important. Questions such as whether the person is short of breath, runs out of breath when speaking, has a weakened cough, or has discomfort swallowing help screen for "severity." Autonomic symptoms such as dizziness, palpitations, and severe blood pressure fluctuations are also regarded as warning signs.
Screening for this disease depends less on testing machines than on clinical detection that does not miss "acute progressive weakness + decreased reflexes + preceding infection."
Diagnosis
The diagnosis is based on the clinical picture and supported by several tests. The first step is the history and neurological examination. It is confirmed how quickly the symptoms progressed, where they started, whether they are symmetric, whether there are clues suggesting other causes such as fever, and whether there are breathing or swallowing problems.
As ancillary tests, nerve conduction studies and electromyography are important. In acute inflammatory demyelinating polyneuropathy, changes suggesting demyelination may appear, such as slowed nerve conduction velocity, findings in which the electrical signal is not transmitted well partway along the nerve (conduction block), and prolonged distal latency. However, early in the course (especially the first 1 to 2 weeks), the test results may not be clear, so repeat testing can be helpful if necessary.
Another key test is cerebrospinal fluid analysis obtained by lumbar puncture (spinal tap). In this disease, a pattern in which protein is elevated but inflammatory cells are not greatly increased is common. However, this finding can also be normal early on, so the disease cannot be "ruled out because the result is normal."
Blood tests are performed to exclude other causes. Because acute paralysis can also appear with many causes such as electrolyte abnormalities like hypokalemia, spinal cord compression, muscle disease, neuromuscular junction disease, drugs or toxins, and infectious neuritis, other causes are excluded with spinal MRI and other tests when clinically suspected. The goals of diagnosis are "to quickly assign the correct diagnosis so as not to miss the window for treatment" and "to safely exclude other similar diseases."
Treatment
Treatment has two broad axes. One is to change the progression of the disease and the speed of recovery with immunotherapy, and the other is to prevent complications with intensive-level supportive care.
If muscle weakness is pronounced or severe enough to make walking difficult, intravenous immunoglobulin (IVIg) or plasma exchange is used as standard treatment. The two treatments are known to have similar effectiveness and are chosen according to the patient's condition and the hospital's circumstances. Because there is evidence that corticosteroids alone do not have a clear effect, they are generally not used as standard treatment. In recent studies, targeted therapies that inhibit the complement pathway are being investigated for patients who do not respond sufficiently to existing treatments.
Supportive care is also very important. Because there is a risk of respiratory failure, vital capacity and respiratory status are assessed frequently, and if necessary, mechanical ventilation is provided in the intensive care unit. Because heart rate and blood pressure can fluctuate greatly due to autonomic abnormalities, electrocardiographic monitoring and blood pressure management may be needed. If there is a swallowing disorder, the risk of aspiration increases, so the method of nutritional support is adjusted.
After the acute phase, rehabilitation becomes the key to recovery. Because it takes time for strength to return, exercise is advanced step by step to prevent joint contractures and restore walking and balance. Pain and fatigue are also common and must be managed together.
Prognosis
The prognosis varies greatly between individuals. Many patients show considerable recovery over time, but recovery can take weeks to months, and sometimes more than a year. In general, recovery begins gradually after the "plateau phase," when the symptoms no longer worsen.
Factors that can worsen the prognosis include very severe initial paralysis, the need for mechanical ventilation due to respiratory muscle weakness, extensive accompanying axonal damage, and delayed intensive care. Recent studies suggest that factors such as markers of nerve damage in the blood or cerebrospinal fluid may help predict prognosis, but there are still limitations before they reach the stage of wide use in everyday practice.
Death is rare but possible, and can be caused mainly by complications such as respiratory failure, autonomic abnormalities (such as arrhythmias), infection, and blood clots. Conversely, if immunotherapy is received at the appropriate time and breathing and complications are well managed, the prognosis is likely to be good.
Sequelae may include residual weakness in the legs, numbness in the hands and feet, neuropathic pain, and severe fatigue. Because the complaint that "even though I can walk again, my energy has not come back as before" is common, it is more realistic to assess prognosis by looking not only at muscle strength but also at daily function and fatigue.
Prevention
There is no perfect method of prevention. Because the core is an immune malfunction that rarely occurs after an infection, it is realistically difficult to aim for "never getting infected." However, realistic prevention can be thought of in two parts.
First, infection prevention and health management. Hand hygiene, safe food consumption, and basic preventive rules for circulating infections can reduce enteritis and respiratory infections and indirectly lower the risk. Recent studies suggest that outbreaks of certain infections and the occurrence of Guillain-Barré syndrome can move together. However, this is not an area that individuals can fully control.
Second, because early treatment is very important for the prognosis of this disease, the key to prevention effectively lies in "quick recognition and quick medical care." If within a few weeks after a cold or enteritis the legs lose strength, numbness progresses rapidly, or stairs suddenly become difficult, medical care should be sought without delay. In particular, if difficulty breathing, swallowing difficulty, or severe dizziness or palpitations accompany these symptoms, emergency evaluation is needed.
After the acute phase, continuing rehabilitation consistently and adjusting daily life to prevent falls and restore muscle strength constitute "prevention for the long-term prognosis." Prevention of this disease is closer to "catching it before it progresses to a severe stage, preventing complications, and optimizing recovery" than to "complete blocking."